Emerging studies on retatruded, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate promising outcomes in addressing obesity and type 2 diabetes. Initial information from clinical trials show notable reductions in body mass and enhanced glucose regulation. Add